Neurontin, gabapentin, and the 1990s moment

Neurontin is the brand name for gabapentin, a medication originally approved for seizure-related indications and later for certain nerve pain conditions. Over time, gabapentin became widely prescribed in the U.S., including for many off-label uses (meaning: prescribed for conditions not listed on the FDA-approved label). Off-label prescribing by clinicians can be legal and appropriate; what gets legally risky is when a manufacturer promotes off-label uses in ways that violate drug marketing laws.

By the late 1990s and early 2000s, Neurontin had become a major commercial successand a lightning rod for allegations that marketing efforts pushed the drug into unapproved territory, sometimes without strong evidence. Those allegations didn’t stay theoretical. They became court cases, internal-document deep dives, and eventually government settlements that forced a broader conversation about pharmaceutical promotion and medical trust.

What is a seeding trial (and why does it feel like science wearing a sales badge)?

A seeding trial is a clinical study that looks like research on the outside but is designed primarily to influence prescribingoften by recruiting large numbers of clinicians as “investigators,” getting them comfortable with a product, and surrounding them with sponsor interactions that can nudge habits. The data collection may be real, but the primary objective is often commercial: seed the market, grow the “user base,” and turn participants into confident prescribers.

The ethical issue isn’t subtle: seeding trials can involve deception by omission. Investigators may not be told the sponsor’s true purpose. Patients may consent to “a study” without being informed that the study also functions as a marketing instrument. And if the design is weak (no control group, fuzzy endpoints), the scientific value can be limited while the promotional value stays… oddly robust.

In other words: a seeding trial can be a bit like inviting you to a “cooking class” that turns out to be a subscription pitch for a blender you didn’t ask forexcept the blender is a prescription medication and the stakes include patient outcomes and public spending.

Meet STEPS: the trial that defined the Neurontin seeding-trial playbook

The STEPS trial was presented as a phase 4, postmarketing study with an official scientific-sounding aim: examine efficacy, safety, tolerability, and quality of life while titrating gabapentin to effect. But later analysis of litigation-produced documents described STEPS as a seeding triala study “posing as a legitimate scientific study,” heavily intertwined with marketing strategy.

Why so many investigators for so few patients?

One of the most revealing details is the scale and structure: STEPS recruited 772 physician investigators and enrolled 2,759 patientsroughly four patients per investigator. That ratio is unusual if your top priority is efficient, high-quality data. It makes more sense if your top priority is exposure: get hundreds of clinicians involved with the sponsor, the drug, the dosing narrative, and the surrounding educational materials.

A design that raised eyebrows

STEPS used an uncontrolled, unblinded designan approach that can be especially questionable for measuring efficacy. According to the document-based account, external sources questioned the trial’s scientific validity before it even began, including an institutional review board that rejected the protocol for being too vague to support scientific conclusions.

The marketing fingerprint in STEPS (it wasn’t exactly hiding under the couch)

The most important lesson from the Neurontin seeding trial story is that marketing influence doesn’t always show up as a cartoon villain twirling its mustache. It can show up as logistics, incentives, messaging strategy, and quiet measurement of physician behavior.

1) The trial itself was treated as a marketing tactic

Documents reviewed in the STEPS narrative account described the existence of the trialnot its outcomesas a marketing tool in strategic plans. That is a key “seeding” tell: if the sponsor’s internal language emphasizes participation and rollout over scientific findings, you’re not looking at research-first thinking.

2) Investigators were also “targets,” and prescribing was tracked

One of the most jaw-dropping aspects of the STEPS account is how the sponsor reportedly analyzed prescribing behavior connected to participation. For example, one internal analysis compared prescribing before and after investigators attended a STEPS introductory briefing and reported a 38% increase in prescriptions afterward, along with a 10% increase in average prescribed dose. The key ethical point: investigators and patients were not told that this kind of marketing-style measurement was part of the program.

3) Recruitment doubled as promotion (hello, “Shadow Days”)

Patient recruitment wasn’t just a research workflow. The STEPS account describes “Shadow Days,” where epilepsy patients were scheduled heavily so sponsor representatives could be present, encourage enrollment, and promote gabapentin at the same time. If you’re thinking “that sounds like a sales visit wearing a lab coat,” you’re not alone.

4) Incentives and “rewards” that patients weren’t told about

Promotional rewards reportedly included physician perks tied to recruitment milestoneslike a free lunch after enrolling three patients and a free dinner after seven. Even if small compared with a speaking fee, these incentives matter because they shape behavior. And patients, per the account, were not informed that these reward programs existed.

5) Competitive strategy: not just “sell ours,” but “block theirs”

Another feature described in the STEPS documentation is competitor blockingusing the trial to keep physicians occupied so they were less likely to participate in competing drug efforts. That’s not the usual language of hypothesis-driven science. That’s the language of market share.

Litigation, settlements, and the “$430 million” moment

The Neurontin seeding trial story is tightly linked to broader allegations about off-label promotion. A whistleblower lawsuit and related investigations culminated in a widely reported settlement announced in May 2004. Public statements around the settlement described allegations of deceptive marketing, Medicaid fraud, and improper payments tied to off-label prescribing.

In California’s public announcement, the settlement was described as totaling $430 million, including major components tied to federal and state matters. The same announcement stated that Neurontin was approved for epilepsy and post-herpetic neuralgia, while alleging that a large share of prescriptions were for off-label uses, and that promotion included unbalanced CME, a “publication strategy,” and other tactics that could influence prescribing and public spending. The settlement also included a Corporate Integrity Agreement aimed at monitoring sales and marketing practices.

Here’s the big picture: the STEPS trial didn’t exist in a vacuum. It fit into a broader ecosystem where educational events, research participation, publications, and prescriber relationships could be leveraged to expand use of a drug beyond its approved indications.

What the Neurontin seeding trial taught medicine

Trust is a clinical resourceand it’s not renewable on a quarterly schedule

Clinical research depends on trust: patients trust that participation advances knowledge, clinicians trust that study design serves science, and the public trusts that published literature is more than a polished brochure. Seeding trials corrode that trust because they use the appearance of research to accomplish marketing objectives.

“Publication strategy” can be more powerful than a billboard

One reason Neurontin became a landmark example is the attention paid to how research and publication can be used as promotion. A major narrative review based on litigation documents described a multifaceted promotional approach that included advisory boards, consultant meetings, CME delivered by third parties, recruiting “local champions,” and using research and publication planning (including suppressing unfavorable results) as marketing tools.

Weak science can still create strong habits

A seeding trial doesn’t need to generate brilliant data to change behavior. It needs to create familiarity, confidence, and repetitionespecially among clinicians who are busy, trying to help patients, and surrounded by a constant hum of “education” that may not be as neutral as it sounds.

Regulation evolvedbut the core principle stayed the same

U.S. regulators have long emphasized that prescription drug promotion should not be false or misleading. FDA’s Office of Prescription Drug Promotion (OPDP) describes its mission as helping ensure promotion is truthful, balanced, and accurately communicated. And FDA guidance documents on communications to healthcare professionals repeatedly stress that information should be truthful, non-misleading, factual, and appropriately presentedespecially when discussing scientific information that could shape care decisions.

How to spot seeding-trial red flags today

You don’t need subpoena power or a filing cabinet of internal memos to ask smart questions. If you’re a clinician, researcher, student, journalist, or patient, these are practical “red flag” checks that echo what the Neurontin seeding trial revealed.

Red flags for clinicians

• Too many investigators, too few patients: Does the study recruit lots of prescribers with minimal enrollment per site?
• Design too weak for the claims: Unblinded, uncontrolled, fuzzy endpointsespecially when “efficacy” language is used.
• Investigator perks tied to recruitment: meals, travel, “milestone rewards,” speaker opportunities, or prestige boosts.
• Heavy sponsor “presence” in workflow: reps embedded in recruitment, data collection, or site operations.
• Behavior tracking without disclosure: any hint that prescribing patterns are being monitored as an outcome.

Red flags for IRBs, hospitals, and training programs

• Endpoints and entry criteria that don’t support real conclusions (vague measures, moving targets, unclear hypotheses).
• Payment that seems high for the work or structured like a quota.
• Consent forms that talk science but omit sponsor objectives or omit how clinician behavior may be evaluated.
• Outsourced research operations with unclear oversight (CROs can be fineunless the sponsor’s marketing goals drive decisions).

Red flags for patients and families

• Ask the simple question: “What is the main purpose of this study?” If the answer is vague, ask again (politely, but firmly).
• Ask about sponsor involvement: “Who will see my data?” and “How is data quality ensured?”
• Ask about benefits and alternatives: A legitimate study should be transparent about what’s known, what isn’t, and what choices you have.

And a friendly reminder: if you’re currently taking gabapentin (or any prescription), don’t change or stop medication based on a historical marketing case. Medication decisions should be made with a licensed clinician who knows your situation.

Experiences Related to the Neurontin Seeding Trial (Extra Section)

The Neurontin seeding trial story doesn’t land like a tidy textbook case because it’s made of human experiencessome subtle, some uncomfortable, and some painfully instructive. Below are composite, real-world–style experiences that echo the patterns described in public records and analyses of the STEPS era. Think of them as “how it felt on the ground,” told without pretending any single person’s memory is the whole truth.

The community neurologist who thought it was “just a study”

A busy community neurologist agrees to be an investigator because it sounds professionally responsible: postmarketing safety data matters, and the paperwork looks manageable. The sponsor’s kickoff meeting is polished, friendly, and heavy on dosing confidenceless “here’s a hypothesis” and more “here’s how you’ll use this in practice.” The doctor enrolls a handful of patients, gets used to titration language, and starts reaching for gabapentin more oftenpartly because it’s familiar, partly because it feels supported, and partly because the study has made the drug feel like the default tool in the drawer. Months later, the physician reads criticism suggesting the trial’s real goal may have been to change prescribing. The emotion isn’t guilt so much as irritation: “If you wanted marketing, why dress it up as research and put my name on it?”

The study coordinator who noticed the “sales energy”

A clinic coordinatorusually the person who keeps research honest by keeping it organizedfeels the difference immediately. The protocol doesn’t seem designed to answer a crisp question. The sponsor’s presence is unusually hands-on. Recruitment is treated like a scoreboard. There’s talk of “targets,” “momentum,” and “getting sites energized.” The coordinator isn’t shocked by the idea that companies want good recruitment (every trial does), but this feels different: less about data integrity and more about “touches” and “exposure.” The coordinator’s takeaway becomes a career-long rule: when a study is allergic to precise endpoints but obsessed with enrollment volume, something’s off.

The IRB member who kept asking, “What conclusion can you actually reach?”

An IRB reviewer reads a protocol and gets stuck on a basic question: if the outcomes are vague and the design is uncontrolled, what scientific conclusion is the trial honestly built to support? The sponsor’s materials emphasize safety and real-world use, but the study architecture feels like a promotional tour with extra paperwork. The IRB member pushes for tighter endpoints, clearer rationale, and transparency about sponsor objectives. Sometimes that pressure improves a protocol; sometimes it gets met with frustration. The lasting lesson is that ethics review isn’t just about avoiding harm in the consent formit’s about ensuring the study’s purpose is truthful.

The patient who assumed “research” meant “neutral”

A patient with difficult-to-control seizures joins a study believing it’s primarily about learninghelping future patients, improving dosing knowledge, building evidence. The patient may not be wrong about the stated purpose, but they aren’t told about incentives around recruitment or the possibility that clinician prescribing behavior is being evaluated. When patients later hear that a “study” can also be marketing, it can feel like a betrayal of the social contract of research. Many patients still support clinical trialsbut with a new skepticism: “Tell me the whole story, not the brochure story.”

The compliance officer who uses STEPS as a cautionary tale

Years later, compliance teams inside pharmaceutical companies train employees with cases like Neurontin and STEPS in mind. The point isn’t that all postmarketing research is suspect; it’s that mixing promotional goals with research design can create legal exposure and long-term reputational damage. Modern guidance, oversight, and monitoring aim to prevent the “research-shaped marketing” problembut the temptation never fully disappears, because market pressure is persistent. The compliance officer’s simple mantra becomes: “If it’s marketing, call it marketing. If it’s science, build it like science.”

Taken together, these experiences show why the Neurontin seeding trial still matters. It’s not just about one drug or one era. It’s about how easily trust can be redirected by structure, incentives, and narrativeand how hard it is to rebuild once people feel they were enrolled in a story that wasn’t fully disclosed.

Conclusion

The Neurontin seeding trial storycentered on the STEPS trialillustrates how clinical research can be engineered to look like science while functioning as a sophisticated marketing channel. The public record describes a program with a study-like exterior and a market-share interior: lots of investigators, minimal enrollment per site, incentives and sponsor presence around recruitment, and internal attention to whether participation changed prescribing.

The broader takeaway is not “never trust trials.” It’s “trust, but verify.” Ask what the trial is built to conclude. Ask who designed it. Ask what’s disclosed to patients and investigators. The difference between ethical research and research-shaped promotion is often not the presence of datait’s the honesty of purpose.